See more : Yamaha Corporation (YAMCY) Income Statement Analysis – Financial Results
Complete financial analysis of Cosmo Pharmaceuticals N.V. (CMOPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cosmo Pharmaceuticals N.V., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Mars Bancorp, Inc. (MNBP) Income Statement Analysis – Financial Results
- Integral Acquisition Corporation 1 (INTEW) Income Statement Analysis – Financial Results
- IDT Australia Limited (IDT.AX) Income Statement Analysis – Financial Results
- Suyog Telematics Limited (SUYOG.BO) Income Statement Analysis – Financial Results
- Tower Resources plc (TRP.L) Income Statement Analysis – Financial Results
Cosmo Pharmaceuticals N.V. (CMOPF)
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.78M | 102.09M | 65.07M | 60.95M | 62.50M | 65.62M | 67.24M | 67.66M | 60.61M | 79.59M | 56.37M | 59.54M | 33.51M | 32.05M | 26.69M | 34.17M | 21.90M | 15.16M | 15.51M | 11.03M |
| Cost of Revenue | 39.34M | 18.76M | 15.14M | 10.44M | 9.25M | 12.37M | 12.13M | 10.19M | 10.08M | 11.62M | 10.28M | 8.42M | 14.49M | 14.33M | 12.77M | 13.20M | 7.02M | 5.50M | 5.74M | 4.15M |
| Gross Profit | 53.44M | 83.33M | 49.93M | 50.51M | 53.25M | 53.25M | 55.12M | 57.48M | 50.53M | 67.97M | 46.09M | 51.12M | 19.02M | 17.72M | 13.91M | 20.97M | 14.88M | 9.66M | 9.77M | 6.88M |
| Gross Profit Ratio | 57.60% | 81.62% | 76.73% | 82.86% | 85.20% | 81.15% | 81.97% | 84.94% | 83.37% | 85.40% | 81.76% | 85.86% | 56.75% | 55.30% | 52.13% | 61.36% | 67.94% | 63.74% | 62.98% | 62.34% |
| Research & Development | 18.81M | 15.53M | 11.36M | 13.60M | 15.69M | 10.52M | 9.10M | 8.26M | 28.69M | 24.82M | 23.21M | 10.92M | 5.17M | 6.78M | 4.45M | 4.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.80M | 3.13M | 2.47M | 4.15M | 4.61M | 8.34M | 6.39M | 3.66M | 2.23M | 2.25M | 2.03M | 1.47M | 5.69M | 6.22M | 5.33M | 5.55M | 6.63M | 4.66M | 2.48M | 2.30M |
| Selling & Marketing | 602.00K | 419.00K | 339.00K | 337.00K | 5.24M | 9.90M | 9.48M | 140.00K | 47.00K | 1.53M | 30.00K | 81.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 543.00K | 247.00K | 68.00K |
| SG&A | 5.40M | 3.55M | 2.81M | 4.48M | 9.86M | 18.24M | 15.86M | 3.80M | 2.28M | 3.78M | 2.06M | 1.55M | 5.69M | 6.22M | 5.33M | 5.55M | 6.63M | 5.21M | 2.73M | 2.37M |
| Other Expenses | 23.08M | 51.72M | 36.03M | 39.12M | 55.70M | 51.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 248.00K | 308.00K | 490.00K |
| Operating Expenses | 47.29M | 55.27M | 38.83M | 43.60M | 65.56M | 69.87M | 64.72M | 32.08M | 55.97M | 45.76M | 33.15M | 24.67M | 10.11M | 12.92M | 9.47M | 9.79M | 14.66M | 11.47M | 8.48M | 7.64M |
| Cost & Expenses | 86.63M | 74.03M | 53.97M | 54.04M | 74.80M | 82.24M | 76.85M | 42.27M | 66.04M | 57.38M | 43.43M | 33.09M | 24.60M | 27.25M | 22.24M | 22.99M | 21.68M | 16.97M | 14.22M | 11.80M |
| Interest Income | 3.95M | 2.94M | 3.06M | 1.75M | 972.00K | 2.20M | 2.98M | 10.93M | 13.73M | 6.68M | 1.73M | 1.01M | 1.03M | 611.00K | 1.29M | 1.37M | 870.00K | -15.00K | -27.00K | -69.00K |
| Interest Expense | 8.53M | 9.16M | 8.99M | 8.73M | 8.53M | 647.00K | 79.00K | 120.00K | 189.00K | 241.00K | 279.00K | 118.00K | 847.00K | 954.00K | 416.00K | 940.00K | 469.00K | 856.00K | 770.00K | 629.00K |
| Depreciation & Amortization | 13.55M | 13.86M | 7.37M | 6.04M | 5.76M | 4.48M | 3.54M | 3.04M | 8.49M | 8.76M | 8.88M | 2.54M | 2.22M | 2.01M | 1.69M | 1.60M | 1.46M | 1.49M | 902.00K | 793.00K |
| EBITDA | 19.70M | 47.49M | 40.48M | 7.84M | -7.02M | -12.33M | -28.81M | 28.44M | 262.97M | 35.71M | 22.65M | 29.61M | 11.40M | 7.42M | 7.43M | 14.15M | 2.08M | -98.00K | 2.98M | 202.00K |
| EBITDA Ratio | 21.23% | 46.53% | 62.21% | 13.28% | -15.22% | -16.38% | -40.70% | 48.72% | 10.86% | 44.86% | 40.19% | 49.63% | 36.29% | 23.16% | 27.83% | 41.42% | 7.68% | -0.65% | 16.19% | 1.83% |
| Operating Income | 6.15M | 28.06M | 33.11M | 2.06M | -12.31M | -16.62M | -15.50M | 21.01M | 250.30M | 22.21M | 12.94M | 26.46M | 9.94M | 5.41M | 5.73M | 12.55M | 221.00K | -1.59M | 1.61M | -591.00K |
| Operating Income Ratio | 6.62% | 27.48% | 50.89% | 3.37% | -19.69% | -25.33% | -23.05% | 31.04% | 412.99% | 27.91% | 22.95% | 44.43% | 29.66% | 16.89% | 21.48% | 36.73% | 1.01% | -10.49% | 10.38% | -5.36% |
| Total Other Income/Expenses | -4.61M | -3.58M | -9.11M | -13.84M | -9.00M | -838.00K | -16.94M | 6.49M | 3.99M | 86.64M | 58.73M | 368.00K | -847.00K | -343.00K | -416.00K | -940.00K | -68.00K | -1.85M | 21.00K | -629.00K |
| Income Before Tax | 1.53M | 24.47M | 24.00M | -6.93M | -21.30M | -17.46M | -32.43M | 27.49M | 254.29M | 108.85M | 71.67M | 26.89M | 9.09M | 4.46M | 5.32M | 11.61M | 153.00K | 803.00K | 1.31M | -1.22M |
| Income Before Tax Ratio | 1.65% | 23.97% | 36.89% | -11.37% | -34.09% | -26.61% | -48.23% | 40.63% | 419.57% | 136.76% | 127.15% | 45.16% | 27.14% | 13.91% | 19.93% | 33.98% | 0.70% | 5.30% | 8.45% | -11.06% |
| Income Tax Expense | 6.26M | 6.97M | 2.33M | 970.00K | 3.19M | 598.00K | 15.00K | 8.15M | 6.10M | 35.53M | 2.94M | 7.56M | 1.49M | 852.00K | 1.27M | 2.21M | 37.00K | 940.00K | 473.00K | 977.00K |
| Net Income | -4.93M | 17.23M | 21.67M | -7.90M | -24.49M | -18.06M | -32.45M | 19.34M | 248.19M | 73.32M | 68.73M | 19.32M | 7.61M | 3.61M | 4.05M | 9.40M | 116.00K | -137.00K | 838.00K | -2.20M |
| Net Income Ratio | -5.32% | 16.87% | 33.30% | -12.96% | -39.19% | -27.52% | -48.25% | 28.58% | 409.51% | 92.12% | 121.94% | 32.46% | 22.70% | 11.25% | 15.18% | 27.51% | 0.53% | -0.90% | 5.40% | -19.92% |
| EPS | -0.31 | 1.05 | 1.29 | -0.55 | -1.67 | -1.20 | -2.19 | 1.37 | 17.60 | 5.12 | 4.81 | 1.41 | 0.53 | 0.25 | 0.30 | 0.68 | 0.01 | -0.02 | 0.33 | -0.96 |
| EPS Diluted | -0.31 | 1.05 | 1.28 | -0.55 | -1.67 | -1.20 | -2.19 | 1.17 | 17.05 | 5.03 | 4.80 | 1.40 | 0.53 | 0.24 | 0.27 | 0.68 | 0.01 | -0.02 | 0.33 | -0.96 |
| Weighted Avg Shares Out | 16.11M | 16.43M | 16.84M | 14.47M | 14.63M | 15.01M | 14.81M | 14.10M | 14.10M | 14.33M | 14.30M | 13.70M | 14.44M | 14.62M | 13.72M | 13.87M | 13.35M | 8.74M | 2.55M | 2.30M |
| Weighted Avg Shares Out (Dil) | 16.11M | 16.43M | 16.90M | 14.47M | 14.63M | 15.01M | 14.81M | 14.40M | 14.40M | 14.59M | 14.31M | 13.77M | 14.44M | 14.81M | 14.84M | 13.87M | 13.35M | 8.74M | 2.55M | 2.30M |
Source: https://incomestatements.info
Category: Stock Reports